Achieving Ophthalmic Production

By John Teixeira, Associate Director of Commercial Operations, Jubilant HollisterStier

Bringing an ophthalmic treatment to market requires a CMO with unparalleled expertise and unwavering commitment to quality. A partner with state-of-the-art facilities can guarantee efficient and scalable production of ophthalmic solutions, drops, and ointments, and is critical as you navigate the complexities of ophthalmic production from initial formulation to global commercialization.

Jubilant HollisterStier (JHS) stands out as a leader in this field, offering a comprehensive solution for your ophthalmic manufacturing needs. JHS's dedication to quality is evident in their rigorous adherence to regulatory standards. They boast a proven track record with agencies like the US FDA, Health Canada, and the EMA, ensuring a smooth path to market approval. Their team of specialists, with expertise in areas like process development and technology transfer, works collaboratively with you to overcome any challenges that may arise during scale-up.

When it comes to potent compounds, JHS possesses the necessary capabilities and experience to handle them safely and effectively. Their Montreal facility is well-equipped to manage products with a SafeBridge classification of up to 3, providing peace of mind for even the most complex projects.

JHS’s unwavering focus on quality, regulatory expertise, and collaborative approach make them the ideal choice for companies seeking a reliable and experienced CMO for their ophthalmic treatments. Learn how the right paretner can help you navigate the complexities of bringing your vision to life.